CAR T Referral Process: Insights From Kansas : Episode 10

Expert Insights: Key Takeaways & Clinical Pearls on CAR T Therapy in R/R MM

February 7, 2025

By Al-Ola Abdallah, MD
Muhammad Umair Mushtaq, MD

Opinion

Video

Panelists discuss how CAR T therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma, highlighting critical factors for success including patient selection, timing of referral, management of adverse effects, and the importance of coordinated care between academic centers and community practices.

EP: 1.Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM

EP: 2.Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?

EP: 3.Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria

EP: 4.University of Kansas Medical Center Insights: CAR T Referral Process

EP: 5.Reviewing CAR T Mechanism & Treatment Process

EP: 6.Approaches to Bridging Therapy During the CAR T Manufacturing Process

EP: 7.Comanaging Cases of RR/MM in Patients Receiving CAR T

EP: 8.On-going Clinical Trials With CAR T Therapy in Earlier-Line Multiple Myeloma Treatment: Future Perspectives

EP: 9.Expert Insights: 68yM High-Risk R/R MM Post HSCT With Progressive Disease—Next Steps?

Now Viewing

EP: 10.Expert Insights: Key Takeaways & Clinical Pearls on CAR T Therapy in R/R MM

Video content above is prompted by the following:

Please share some key takeaways/pearls.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!